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ABSTRACT OF DISSERTATION

NOVEL APPLICATIONS OF MACHINE LEARNING IN BIOINFORMATICS

Technological advances in next-generation sequencing and biomedical imaging
have led to a rapid increase in biomedical data dimension and acquisition rate, which is
challenging the conventional data analysis strategies. Modern machine learning techniques
promise to leverage large data sets for finding hidden patterns within them, and for making
accurate predictions. This dissertation aims to design novel machine learning-based models
to transform biomedical big data into valuable biological insights. The research presented
in this dissertation focuses on three bioinformatics domains: splice junction classification,
gene regulatory network reconstruction, and lesion detection in mammograms.
A critical step in defining gene structures and mRNA transcript variants is to
accurately identify splice junctions. In the first work, we built the first deep learning-based
splice junction classifier, DeepSplice. It outperforms the state-of-the-art classification tools
in terms of both classification accuracy and computational efficiency. To uncover
transcription factors governing metabolic reprogramming in non-small-cell lung cancer
patients, we developed TFmeta, a machine learning approach to reconstruct relationships
between transcription factors and their target genes in the second work. Our approach
achieves the best performance on benchmark data sets. In the third work, we designed deep
learning-based architectures to perform lesion detection in both 2D and 3D whole
mammogram images.
KEYWORDS: Machine Learning, Deep Learning, Splice Junction, RNA-seq, Cancer,
Biomedical Imaging
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CHAPTER 1. INTRODUCTION

1.1

Machine learning
Machine learning can be broadly described as computational methods using

previous experience to improve performance or to make precise inferences. Here, previous
experience refers to the past information available to the learner. This data could be in the
form of digitized human-labeled training sets, or other types of information obtained via
interaction with the environment. In all cases, its quality and size are crucial to the success
of the predictions made by the learner [1].
The processes involved in machine learning are similar to that of data mining and
predictive modeling. Both require searching through data to look for patterns and adjusting
program actions accordingly. Many people are familiar with machine learning from
shopping on the internet and being served ads related to their purchase. This happens
because recommendation engines use machine learning to personalize online ad delivery
in almost real time. Beyond personalized marketing, other common machine learning use
cases include fraud detection, spam filtering, network security threat detection, predictive
maintenance and building news feeds.
Machine learning algorithms are often categorized as supervised or unsupervised.
Supervised algorithms require both input and desired output, in addition to furnishing
feedback about the accuracy of predictions during algorithm training. Once training is
complete, the algorithm will apply what was learned to new data. Unsupervised algorithms
do not need to be trained with desired outcome data.
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Since the success of a learning algorithm depends on the data used, machine
learning is inherently related to data analysis and statistics. More generally, machine
learning techniques are data-driven methods combining fundamental concepts in computer
science with ideas from statistics, probability and optimization [1].
The standard machine learning tasks which have been extensively studied are listed
as follows:
 Classification: classification is used when the outputs are restricted to a limited set
of values. For a classification task that filters emails, the input would be an incoming
email, and the output would be the name of the folder in which to file the email [2].
 Regression: regression is adopted to predict continuous outputs, that is, real values
within a range. Examples of a continuous value are the temperature, length, or price
of an object [2].
 Ranking: ranking is to produce a permutation of items in unseen lists in a way which
is similar to rankings in the training data in some sense. Ranking is a central part of
many information retrieval problems, such as document retrieval, sentiment analysis,
and online advertising [3].
 Clustering: clustering is the task of grouping a set of objects in such a way that
objects in the same group are more similar to each other than to those in other groups.
For instance, in social network analysis, clustering algorithms try to identify natural
communities within a large group of people [4].
 Dimensionality reduction: dimensionality reduction is to transform an initial
representation of items into a lower-dimensional representation while preserving some
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properties of the initial representation. A common example involves preprocessing
digital images in computer vision tasks [1].

1.2

Deep learning
Deep learning is a branch of machine learning, which employs numerous similar

but distinct deep neural network architectures to solve various problems in natural language
processing, computer vision, and bioinformatics, among other fields. Deep learning has
experienced tremendous recent research resurgence, and has been shown to deliver state of
the art results in numerous applications.
In essence, deep learning is the implementation of neural networks with more than
a single hidden layer of neurons, as shown in Figure 1.1. However, this is a very simplistic
view of deep learning, and not one that is unanimously agreed upon. These "deep"
architectures also vary quite considerably, with different implementations being optimized
for different tasks or goals. The vast research being produced at such a constant rate is
revealing new and innovative deep learning models at an ever-increasing pace.
The successes of deep learning are built on a foundation of significant algorithmic
details and generally can be understood in two parts: construction and training of deep
learning architectures [5]. Deep learning architectures are basically artificial neural
networks of multiple non-linear layers and several types have been proposed according to
input data characteristics and research objectives. Here, we categorized deep learning
architectures into four groups: deep neural networks (DNNs), convolutional neural
networks (CNNs), recurrent neural networks (RNNs) and emergent architectures. DNNs
include multilayer perceptron (MLP), stacked auto-encoder (SAE) and deep belief
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networks (DBNs), which use perceptrons, auto-encoders and restricted Boltzmann
machines as the building blocks of neural networks, respectively. CNNs are architectures
that have succeeded particularly in image recognition and consist of convolution layers,
non-linear layers and pooling layers. RNNs are designed to utilize sequential information
of input data with cyclic connections among building blocks like perceptrons, long shortterm memory units or gated recurrent units. In addition, many other emergent deep learning
architectures have been suggested, such as deep spatio-temporal neural networks (DSTNNs), multidimensional recurrent neural networks (MD-RNNs) and convolutional autoencoders (CAEs).

Figure 1.1 Illustration of the deep neural network layers.

The goal of training deep learning architectures is optimization of the weight
parameters in each layer, which gradually combines simpler features into complex features
so that the most suitable hierarchical representations can be learned from data. A single
cycle of the optimization process is organized as follows. First, given a training dataset,
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the forward pass sequentially computes the output in each layer and propagates the function
signals forward through the network. In the final output layer, an objective loss function
measures error between the inferred outputs and the given labels. To minimize the training
error, the backward pass uses the chain rule to backpropagate error signals and compute
gradients with respect to all weights throughout the neural network. Finally, the weight
parameters are updated using optimization algorithms based on stochastic gradient descent
(SGD). Whereas batch gradient descent performs parameter updates for each complete
dataset, SGD provides stochastic approximations by performing the updates for each small
set of data examples. Several optimization algorithms stem from SGD. For example,
Adagrad and Adam perform SGD while adaptively modifying learning rates based on
update frequency and moments of the gradients for each parameter, respectively.
Another core element in the training of deep learning architectures is regularization,
which refers to strategies intended to avoid overfitting and thus achieve good
generalization performance. For example, weight decay, a well-known conventional
approach, adds a penalty term to the objective loss function so that weight parameters
converge to smaller absolute values. Currently, the most widely used regularization
approach is dropout. Dropout randomly removes hidden units from neural networks during
training and can be considered an ensemble of possible subnetworks. Furthermore, recently
proposed batch normalization provides a new regularization method through normalization
of scalar features for each activation within a mini-batch and learning each mean and
variance as parameters.

5

1.3

Machine learning in bioinformatics
In the era of big data, the rapid increase in biomedical data dimension and

acquisition rate is challenging conventional analysis strategies. Modern machine learning
methods, such as deep learning, promise to leverage large data sets for finding hidden
structure within them, and for making accurate predictions.
The potential of machine learning in analyzing biomedical data sets is clear: in
principle, it allows to better exploit the availability of increasingly large and highdimensional data sets by training complex models that capture their internal structure. The
learned models discover high-level features, increase interpretability and provide
additional understanding about the structure of the biomedical data [6].
Recent papers are trying to apply machine learning to omics, biomedical imaging,
electronic health record, and numerous other bioinformatics domains.

1.3.1

Omics
Improvements in technology have fueled the proliferation of omics applications.

These techniques are often used to measure and study complex biological systems and their
interactions. Omics includes a multitude of areas of focus such as genomics,
transcriptomics,

proteomics,

interactomics,

metabolomics,

phenomics,

and

pharmacogenomics to name, but a few. Each one of these areas might also have many
subdomains, each requiring further specialization in analytical and computational
approaches [7].
Increasingly, the scale of omics data generation has been challenging researchers'
abilities to integrate and model often noisy, complex, and high-dimensional data. Machine
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learning has emerged as a powerful approach, which can both encode and model many
forms of complex data both in supervised and unsupervised settings. DeepBind has been
built to predict the sequence specificities of DNA- and RNA-binding proteins by deep
learning [8]. Chen et al. [9] designed a machine learning-based method, D-GEX, to infer
the expression of target genes from the expression of landmark genes. Arvaniti et al.
proposed CellCnn [10], a representation learning approach to detect rare cell subsets
associated with disease using high-dimensional single-cell measurements. Ma et al.
developed DCell [11], a visible neural networks embedded in the hierarchical structure of
2,526 subsystems comprising a eukaryotic cell. Trained on several million genotypes,
DCell simulates cellular growth nearly as accurately as laboratory observations. Altae-Tran
et al. [12] introduced a new deep-learning architecture, the iterative refinement long shortterm memory, a modification of the matching-networks architecture and the residual
convolutional network. The architecture allows for the learning of sophisticated metrics
which can trade information between evidence and query molecules. The authors
demonstrated that their architecture offers significant boosts in predictive power for a
variety of problems meaningful for low-data drug discovery.

1.3.2

Biomedical imaging
Over the recent years, machine learning has had a tremendous impact on various

fields in science. It has led to significant improvements in speech recognition and image
recognition, it is able to train artificial agents that beat human players in Go and ATARI
games, and it creates artistic new images, and music. Many of these tasks were considered
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to be impossible to be solved by computers [13]. Obviously this technology is also highly
relevant for biomedical imaging.
The advantage of machine learning in an era of biomedical imaging big data is that
significant hierarchal relationships within the data can be discovered algorithmically
without laborious hand-crafting of features. The key machine learning applications in
biomedical imaging include image classification, localization and detection, segmentation,
and image reconstruction. Esteva et al. [14] demonstrated the effectiveness of deep
learning in dermatology, a technique applied to both general skin conditions and specific
cancers. Using a single convolutional neural network trained on general skin lesion
classification, the authors matched the performance of at least 21 dermatologists tested
across three critical diagnostic tasks: keratinocyte carcinoma classification, melanoma
classification and melanoma classification using dermoscopy. Chlebus et al. [15]
developed a fully automatic method for liver tumor segmentation in CT images based on a
2D fully convolutional neural network with an object-based postprocessing step. Inspired
by the sharp, high texture-quality images retrieved by GANs, and the high contrast of MR
images, Mardani et al. [16] employed GANs for modeling the low-dimensional manifold
of high-quality MR images. This framework can leverage the historical data for rapid and
high

diagnostic-quality

image

reconstruction

from

highly undersampled

MR

measurements.

1.3.3

Electronic health record
Over the past 10 years, hospital adoption of electronic health record (EHR) systems

has skyrocketed, in part due to the Health Information Technology for Economic and
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Clinical Health (HITECH) Act of 2009, which provided $30 billion in incentives for
hospitals and physician practices to adopt EHR systems [17]. According to the latest report
from the Office of the National Coordinator for Health Information Technology (ONC),
nearly 84% of hospitals have adopted at least a basic EHR system, a 9-fold increase since
2008 [18]. Given the increasingly vast amount of patient data and the rise in popularity of
machine learning approaches, there has also been an increase in the number of publications
applying machine learning to EHR data for clinical informatics tasks which yield better
performance than traditional methods and require less time-consuming preprocessing and
feature engineering.
Miotto et al. [19] presented a novel unsupervised deep feature learning method to
derive a general-purpose patient representation from EHR data that facilitates clinical
predictive modeling. In particular, a three-layer stack of denoising autoencoders was used
to capture hierarchical regularities and dependencies in the aggregated EHRs. The authors
reported that their findings indicate that deep learning applied to EHRs can derive patient
representations that offer improved clinical predictions, and could provide a machine
learning framework for augmenting clinical decision systems. Rajkomar et al. [20]
proposed a representation of patients’ entire raw EHR records based on the Fast Healthcare
Interoperability Resources (FHIR) format. The authors demonstrated that deep learning
methods using their representation are capable of accurately predicting multiple medical
events from multiple centers without site-specific data harmonization, and their models
outperformed traditional, clinically-used predictive models in all cases. Chen et al. [21]
developed NoteAid, a natural language processing system that links medical terms in EHR
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notes to lay definitions targeted at or below the average adult literacy level to support
patient EHR comprehension.

1.4

Dissertation statement
This dissertation aims to design novel machine learning-based models to transform

biomedical big data into valuable biological insights. It covers three different but closely
related bioinformatics domains of great importance, including: classification of splice
junction sequences using convolutional neural networks, reconstruction of gene regulatory
networks using gradient boosted trees, and detection of lesions in mammogram images
using deep learning.

1.5

Contributions of this dissertation
We have developed a series of novel machine learning-based approaches for

analyzing various biomedical data, including genomics data, transcriptomics data, and
biomedical imaging data. The performance of each of those approaches is assessed using
a number of simulated and real datasets. The experiments demonstrate their advantages on
accuracy and efficiency compared to other state-of-the-art approaches. This dissertation
may contribute to the following three areas.
 Accurate classification of novel splice junctions derived from RNA-seq
alignment

A model inferred from the sequences of annotated exon junctions

that can then classify splice junctions derived from primary RNA-seq data has been
developed. Our DeepSplice model is the first deep learning-based splice junction
classifier. The performance of the model was evaluated and compared through
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comprehensive benchmarking and testing, indicating a reliable performance and gross
usability for classifying novel splice junctions derived from RNA-seq alignment. Our
findings further indicate that valuable information is present in the nucleotide
sequence local to the splice junction, data that conventional splice site prediction
techniques discard.
 Efficient reconstruction of gene regulatory networks using multi-omics data
sets

Leveraging gradient boosted trees, a multi-omics approach to uncover TFs

governing cancer metabolic reprogramming and reconstruct their interactions with
metabolic enzymes has been designed. We demonstrated that TFmeta achieved stateof-the-art performance in recovering TF-target gene interactions on public benchmark
data sets. We applied our model to non-small-cell lung cancer patients’ data sets to
predict TFs modulating the dysregulation of glycolysis in lung cancer, leveraging the
pairing information of the samples and TF DNA binding activities. Eventually, we
predicted a list of key TFs that may motivate the upregulation of glycolysis observed
in tumor cells, some of which have been supported by literature evidence, and some
of which were predicted as novel putative TFs in lung cancer.
 Precise detection of lesions in 2D and 3D mammography images

We

conducted the first work that study both 2D and 3D mammography images for breast
cancer classification through deep learning. We evaluated ten different convolutional
neural network architectures and concluded that combining both data augmentation
and transfer learning methods with a convolutional neural network is the most
effective in improving classification performance. Our work sheds light on how each
type of data sets performs when trained independently. 2D and 3D images are
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complementary to each other, where 2D offers high resolution while 3D offers
multiple views. Our work suggests the development of assembled classifiers that
integrate the 2D and 3D data to achieve optimal performance.
The software packages for the algorithms developed in this dissertation are open
source and publicly available to the research community.
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CHAPTER 2. DISCERNING NOVEL SPLICE JUNCTIONS REVEALED BY RNA-SEQ WITH
DEEPSPLICE
Exon splicing is a regulated cellular process in the transcription of protein-coding
genes. Technological advancements and cost reductions in RNA sequencing have made
quantitative and qualitative assessments of the transcriptome both possible and widely
available. RNA-seq provides unprecedented resolution to identify gene structures and
resolve the diversity of splicing variants. However, currently available ab initio aligners
are vulnerable to spurious alignments due to random sequence matches and samplereference genome discordance. As a consequence, a significant set of false positive exon
junction predictions would be introduced, which will further confuse downstream analyses
of splice variant discovery and abundance estimation.
In this chapter, we present a deep learning based splice junction sequence classifier,
named DeepSplice [22], which employs convolutional neural networks to classify
candidate splice junctions. We show (I) DeepSplice outperforms state-of-the-art methods
for splice site classification when applied to the popular benchmark dataset HS3D, (II)
DeepSplice shows high accuracy for splice junction classification with GENCODE
annotation, and (III) the application of DeepSplice to classify putative splice junctions
generated by Rail-RNA alignment of 21,504 human RNA-seq data significantly reduces
43 million candidates into around 3 million highly confident novel splice junctions.

2.1

Introduction
Technological improvements, reduced cost, and accessibility of RNA sequencing

technologies have provided unprecedented visibility of the transcriptome through the deep
sequencing of all mRNA transcripts present in a sample. Through analyses of mRNA-seq
13

data, researchers now believe that 92–94% of mammalian protein-coding genes undergo
alternative splicing, with roughly 86% of these containing a minor transcript isoform
frequency of at least 15% in certain cell types, developmental time points, physiological
states, or other conditions [23]. This is an 87-89% increase from forty years ago when
alternative exon structures from a single gene locus were first introduced and it was
believed that only around 5% of genes in higher eukaryotes undergo alternative splicing
[24].
The approach to defining exon junctions from RNA-seq data utilizes the subset of
reads that have a gapped alignment to the reference genome. These reads can be aligned to
two or more exons, indicating that there exist junctions joining adjacent exons. Whereas
some mapping strategies [25-28] require pre-defined structural annotation of exon
coordinates, more recently developed algorithms [29-33] can conduct ab initio alignment,
which means that they do not rely on the existence of predetermined gene structure
annotation and can potentially identify novel splice junctions between exons by the
evidence of spliced alignments.
The accurate prediction of exon junctions is essential for defining gene structures
and mRNA transcript variants. Splicing must be absolutely precise because the deletion or
addition of even a single nucleotide at the splice junction would throw the subsequent
three-base codon translation of the RNA out of frame [34]. However, novel splice junctions
predicted by read alignments are not totally reliable, since the possibility of randomly
mapping a short read up to 150 bases to the large reference genome is high [35], especially
when gapped alignments with short anchoring sequences are permitted. In a recent report
by Nellore et al [36] that investigated splicing variation, 21,504 RNA-seq samples from
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the Sequenced Read Archive (SRA) were aligned to the human hg19 reference genome
with Rail-RNA [37], identifying 42 million putative splice junctions in total. This value is
125 times the number of total annotated splice junctions in humans, making it impossible
to admit that all of them actually exist. False positive splice junctions may lead to false
edges in splice graphs, significantly increasing the complexity of the graphical structures
[38]. Consequentially, this will impact the accuracy of splice variant inference algorithms
as they often start from splice graphs derived from RNA-seq alignment [39].
Conventional strategies designed to filter out false positive exon splice junctions
depend primarily on two properties: (1) the number and the diversity of reads mapped to
the given splice junction [35]; and/or (2) the number of independent samples in which the
specific exon splice junction is identified [35, 40]. In general, higher read support and
sample reoccurrence rate both enlarge the likelihood of being a true splice junction. These
criteria have a positive correlation with the number of read alignments, which are
dependent on the sampling depth of the particular sample. Exact thresholds are difficult to
set due to varying sampling depth across samples. Additionally, due to both sequencing
and alignment errors, a splice junction with both high read support and high sample
reoccurrence may still be the result of systematic bias. In contrast, a splice junction that
exists in a transcript with relatively low expression may still be functionally important [41].
Thus, further classification of putative splice junctions revealed by RNA-seq data is still
necessary but remains a challenging issue.
Since the 1980s, a number of bioinformatic approaches have been developed for
splice site prediction. Neural networks [42-44], support vector machines [45-47], hidden
Markov model [48-50], deep Boltzmann machines [51] and discriminant analysis [52, 53]
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have been applied to recognize splice sites in the reference genome of many given species.
Neural networks, support vector machines and deep Boltzmann machines learn the
complex features of neighborhoods surrounding the consensus dinucleotide AG/GT by a
non-linear transformation. Hidden Markov models estimate position specific probabilities
of splice sites by computing the likelihoods of candidate signal sequences. The
discriminant analysis uses several statistical measures to evaluate the presence of specific
nucleotides, recognizing splice sites without explicitly determining the probability
distributions [50]. However, all these work treat donor and acceptor sites as independent
events, failing to leverage the inherent relationships between the donor and acceptor during
splicing.
In this work, we develop a deep neural network-based approach to the classification
of potential splice junctions. Our method is applicable to both splice site prediction and
splice junction classification. First, instead of treating donor or acceptor splice sites
individually, our method models the donor and acceptor splice sites as a functional pair.
Thus, it is capable of capturing the remote relationships between features in both donor and
acceptor sites that determine the splicing. Additionally, flanking subsequences from both
exonic and intronic sides of the donor and acceptor splice sites will be used for learning
and prediction, making it possible to understand the contribution of both coding and noncoding genomic sequences to the splicing. Our approach does not rely on sequencing read
support or frequency of occurrence derived from experimental RNA-seq data sets, thus can
be applied as an independent evidence for splice junction validation. Our experiments
demonstrate that DeepSplice outperforms other state-of-the-art approaches [50, 54-58]
when tested against a benchmarking dataset, Homo Sapiens Splice Sites Database (HS3D),
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using a variety of evaluation metrics. Trained on an older version of the GENCODE project
gene annotation data [59], we show that our algorithm can predict the newly annotated
splice junctions with high accuracy and performs better than splice site-based approach.
The application of DeepSplice to further classify putative intropolis human splice junction
data by Nellore et al [36] is able to eliminate around 83% unannotated splice junctions. We
discover that the combinational information from the functional pairing of donor and
acceptor sites facilitates the recognition of splice junctions and demonstrate from large
amounts of sequencing data that non-coding genomic sequences contribute much more
than coding sequences to the location of splice junctions [47, 60].

2.2

DeepSplice method
DeepSplice employs a convolutional neural network (CNN, or ConvNet) to

understand sequence features that characterize real splice junctions [61]. The overall
architecture of DeepSplice is shown in Figure 2.1. In the supervised training step, CNN
learns features that help to differentiate actual splice junctions from fake ones. In the
inference step, the trained model uses the genomic sequence of the candidate splice
junction and predicts the probability of it being a real splice junction. Deep Taylor
decomposition [62] of the CNN is used to explain to what extent each nucleotide in the
candidate splice junction has contributed to the inference.
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Figure 2.1 Visualization of splice junction sequence representation and deep convolutional
neural network in DeepSplice. Each sequence is converted into a tensor through one-hot
encoding in the pre-processing of the sequence representation. The tensor is fed as original
input to the deep convolutional neural network, which contains one input layer, two
convolutional layers, one fully connected layer (FCN) and one output layer. The
convolutional neural network transforms the nucleotide signal in splice junction sequences
to the final label of class.

2.2.1

Splice junction representation
A splice junction sequence is represented by four subsequences, the upstream

exonic subsequence and downstream intronic subsequence at the donor site, and the
upstream intronic subsequence and downstream exonic subsequence at the acceptor site,
as shown in Figure 2.1. Each subsequence has the length of 30, which is believed to be
optimal for splice site/junction prediction [41, 44, 48, 49, 63]. Nucleotides in each sequence
are represented through one-hot encoding. In the proposed encoding system, the
orthonormal sparse encoding is used for the four definite values (A, C, G and T) as it has
been used widely in the numerical representations of biological sequences [64]. But for the
ambiguous base N, instead of disregarding it or giving it the same importance as the definite
values, the probability is used.

18

Each splice junction sequence is transformed into a 3-dimensional tensor. The first
dimension ‘height’ is equal to one, and the second dimension ‘width’ indexes the sequence
length, that is, the number of nucleotides in the sequence, and the third dimension
‘channels’ indexes the type of nucleotide. The tensors are fed as input to deep convolutional
neural networks for downstream processing.

2.2.2

Deep convolutional neural network
DeepSplice contains a multi-layer feedforward neural network. We stack one input

layer, two convolutional layers, one fully connected layer, and one output layer. The whole
network architecture can be written as follows:
𝐿𝑎𝑏𝑒𝑙 𝑜𝑓 𝑐𝑙𝑎𝑠𝑠 = 𝑓𝑓𝑐𝑛 (𝑓𝑐𝑜𝑛𝑣2 (𝑓𝑐𝑜𝑛𝑣1 (𝑆𝑒𝑞𝑢𝑒𝑛𝑐𝑒 𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑖𝑑𝑒 𝑠𝑖𝑔𝑛𝑎𝑙)).
In this way, the convolutional neural network transforms the nucleotide signal in splice
junction sequences to the final label of class as shown in Figure 2.1.
In the first convolutional layer, the convolution will compute 8 features over the
input tensor which represents splice junction sequence, which results in 8 feature maps of
the input tensor. In order to reason the complex nonlinearity between inputs and outputs,
we further stack the second convolutional layer computing 16 features over 8 feature maps
from the first convolutional layer. In the convolutional layers, the filters have size 3x1.
During the forward pass, we slide each filter along the splice junction sequence and
compute dot products between the filter and the input tensor. As we slide the filter over the
input splice junction sequence we will produce feature maps that give the responses of that
filter at every spatial position. After two convolutional layers, the features are presented in
16 tensors. The output of the second convolutional layer is taken by a fully connected layer
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with 32 feature maps for high-level reasoning. The fully connected layer is followed by the
output layer indicating the final label of class. In the neural network, all parameters are
learned during training to minimize a loss function which captures the difference between
the true labels of class and predicted values.
Training the network follows the standard backpropagation and optimizes the loss
function using Adam [65]. Advance deep learning techniques L2 regularization [66],
dropout [67] and mini-batch gradient descent [68] are deployed to regularize the network
to prevent over-fitting and to accelerate the training process.
In the reference step, testing splice junction sequences transformed by one-hot
encoding are fed to the learned network for a binary classification, which outputs the
predicted label of the class, true or false splice junction.

2.2.3

Deep Taylor decomposition of deep convolutional neural network
We propose to use deep Taylor decomposition [62] to explain the contribution of

nucleotides in the splice junction sequence to the final decision function of the deep
convolutional neural network, as shown in Figure 2.2. Taking image recognition task as an
example, such decomposition results in a “heat map” that indicates what pixels of the image
are important for a neural network classification. In our application, for testing splice
junction sequence 𝐒, we would like to associate to nucleotide 𝑛 a contribution score 𝐶𝑛 (𝐒)
from which it is possible to judge which nucleotides are of importance to explain the
predicted label of class from the deep convolutional neural network.
Deep Taylor decomposition operates by running a backward pass on the trained
convolutional neural network using a predefined set of rules. Backpropagating from the
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function output down to the input, it results in assigning a set of scores 𝐂(𝐒) = {𝐶𝑛 (𝐒)} to
the nucleotides in the input testing splice junction sequence 𝐒 to quantify their contributions
to the predicted label of class.

Figure 2.2 Visualization of deep Taylor decomposition in DeepSplice. Deep Taylor
decomposition explains the contribution of each nucleotide in the splice junction sequence
to the final decision function of the deep convolutional neural network. Deep Taylor
decomposition operates by running a backward pass on the trained convolutional neural
network using a predefined set of rules.

2.2.4

Other deep learning architectures
To decipher the abilities of different deep learning architectures in handling splice

junction sequence data, we further build multilayer perceptron network (MLP) and long
short-term memory network (LSTM) to compare with convolutional neural network. MLP
is a feedforward artificial neural network with multiple hidden layers of units between input
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and output layers. LSTM is a recurrent neural network architecture where connections
between units form a directed cycle.
The multilayer perceptron network is composed of one input layer, four hidden
layers and one output layer. Each layer is fully connected to next layer in the network. The
number of neurons in each hidden layer is 64, 128, 128 and 256 respectively. In the long
short-term memory network, we deploy one input layer, three hidden layers and one output
layer. Each of the three hidden layers contains 16 LSTM cells. For both architectures, the
inputs are splice junction sequences transformed by one-hot encoding, and the outputs are
class labels. Advance deep learning techniques, dropout [67], regularization [66], minibatch gradient descent [68] and Adam [65], are exploited in the supervised training steps
in both networks.

2.2.5

Filtering of false splice junction as a result of repetitive sequences
One potential resource of false positive splice junction is the inability to align a

sequence to the correct sites due to higher mismatches than the threshold set by aligners or
small indels that cannot be detected by aligners. Before the classification of splice
junctions, we first remove the splice junctions whose sequence at the acceptor (donor) site
has high sequence similarity with the immediate flanking sequence next to the donor
(acceptor) site or the sequence at any of its alternative acceptor (donor) sites, as shown in
Figure 2.3. The edit distance between the alternative acceptor (donor) site sequences is
computed using the Smith-Waterman algorithm [69]. This filtering strategy is independent
of read coverage and enables the retention of correct splice junctions even with low read
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coverage. The removal of these sequences is necessary as most of them are highly similar
with one of the splice junctions remaining in the data set.

Figure 2.3 Illustration of splice junction filtering strategy. In this example, two edit
distances are calculated. One (Ed) is between anchor sequence at donor site (G[JdAd+1:Jd]) and intermediate flanking sequence next to acceptor site (G[Ja-Aa:Ja-1]). The
other (Ea) is between anchor sequence at acceptor site (G[Ja:Ja+Aa-1]) and intermediate
flanking sequence next to donor site (G[Jd+1:Jd+Ad]).

2.2.6

Implementation and performance measures
The deep learning architectures are implemented using TensorFlow [70]. Training

and testing are deployed on Nvidia GeForce GTX 1080 graphics cards. DeepSplice is
freely

available

for

academic

use

and

can

be

accessible

at

https://github.com/zhangyimc/DeepSplice.
We employ the following metrics: Area Under the ROC Curve (auROC), Area
Under the Precision Recall Curve (auPRC), sensitivity, specificity, accuracy, F measure
and 𝑄 9 . 𝑄 9 is independent of the class distribution in the data set and is used to evaluate
the classifier performance on splice site prediction [57].
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2.3

Experimental results
We first applied our approach to a benchmark dataset HS3D [71] and compared the

performance with other state-of-the-art approaches for donor and acceptor splice site
classification. We then evaluated DeepSplice’s performance by classifying annotated
splice junctions from GENCODE gene annotation data [59]. Deep Taylor decomposition
[62] was then applied for further interpretation of base level contribution of flanking splice
sequence. Finally, we applied DeepSplice to intropolis [36], a newly published splice
junction database with 42,882,032 splice junctions derived from 21,504 samples. The
detailed results are described below.

2.3.1

DeepSplice outperforms state-of-the-art splice site prediction method
We

utilized

HS3D

[71]

(Homo

Sapiens

Splice

Sites

Data

set,

http://www.sci.unisannio.it/docenti/rampone/), a popular benchmark for measuring the
quality of splice site classification methods. HS3D includes introns, exons and splice site
sequences extracted from GeneBank Rel. 123. The splice site sequences in HS3D are with
the length of 140 nucleotides. There are 2796 (2880) true donor (acceptor) splice sites and
271,937 (329,374) false donor (acceptor) splice sites which all contain conserved GT (AG)
dinucleotides. We constructed the 1:10 data set, which contains all the true splice sites and
27,960 (28,800) randomly selected false donor (acceptor) splice sites. Binary
classifications were conducted to identify the actual splice sites on donor and acceptor
splice site data separately.
DeepSplice was trained on donor and acceptor splice site sequences separately in
order to compare with state-of-the-art approaches of splice site classification. The exact
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same number of training and testing splice site sequences from HS3D were used for all
approaches. Table 2.1 summarizes the classification accuracies on the 1:10 data set by 10fold cross-validation. To measure the quality of the classification results, we employed
sensitivity, specificity, and 𝑄 9 which is the global accuracy measure calculated from both
sensitivity and specificity scores. Since the published splice site classification methods do
not provide public tools for training and testing, the results of SVM+B [54], MM1-SVM
[50], DM-SVM [55], MEM [56] and LVMM2 [57] were obtained from [55, 57]. As shown
in Table 2.1, DeepSplice outperforms other methods in both sensitivity and specificity for
both donor and acceptor splice site classification. For donor splice sites, there is a 95%
likelihood that the confidence interval [0.0581, 0.0633] covers the true classification error
of DeepSplice on the testing data. For acceptor splice sites, there is a 95% likelihood that
the confidence interval [0.0814, 0.0872] covers the true classification error of DeepSplice
on the testing data.

Table 2.1 Evaluation of DeepSplice and state-of-the-art approaches for donor (acceptor)
site classification on HS3D data set
Donor
Sensitivity Specificity
LS-GKM
0.8679
0.8516
SVM+B
0.9406
0.9067
MM1-SVM 0.9256
0.9244
DM-SVM
0.9469
0.9339
MEM
0.9324
0.9275
LVMM2
0.9424
0.9242
DeepSplice 0.9571
0.9376

9

𝑄
0.8595
0.9212
0.9247
0.9399
0.9295
0.9323
0.9465
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Acceptor
Sensitivity Specificity
0.8403
0.8319
0.9066
0.8797
0.8993
0.8869
0.9215
0.9073
0.9153
0.8843
0.9122
0.8970
0.9337
0.9139

𝑄9
0.8361
0.8920
0.8926
0.9136
0.8978
0.9039
0.9232

To deduce the most suitable architecture for learning the patterns in splice
site/junction sequences, we then compared DeepSplice against two other prominent types
of neural networks, multilayer perceptron network and long short-term memory network,
in terms of classifying HS3D data set by 10-fold cross-validation. As shown in Figure 2.4,
DeepSplice with convolutional neural network exceeds the other architectures, achieving
an auROC score of 0.983 (0.974) on donor (acceptor) splice site classification and an
auPRC score of 0.863 (0.800) on donor (acceptor) splice site classification. LSTM
achieved an auROC score of 0.960 (0.942) on donor (acceptor) splice site classification
and an auPRC score of 0.803 (0.721) on donor (acceptor) splice site classification. MLP
achieved an auROC score of 0.931 (0.914) on donor (acceptor) splice site classification
and an auPRC score of 0.650 (0.559) on donor (acceptor) splice site classification. In
general, convolutional neural network is a well-studied architecture, which outperforms
other deep learning architectures in almost all kinds of applications currently [72]. Even
for speech recognition, convolutional neural networks recently beat recurrent neural
networks. In our application, convolutional layers efficiently learned the complex
information of nucleotide neighborhoods.
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Figure 2.4 The ROC curves of DeepSplice, multilayer perceptron network (MLP) and long
short-term memory network (LSTM) for donor (acceptor) splice site classification on the
HS3D data set by 10-fold cross-validation. DeepSplice with convolutional neural network
exceeds the other deep learning architectures, achieving an auROC score of 0.983 (0.974)
on donor (acceptor) splice site classification.

2.3.2

DeepSplice predicts newly annotated splice junctions with high accuracy
Next, we evaluated the accuracy of DeepSplice in terms of splice junction

classification. To achieve this, we trained DeepSplice using splice junctions extracted from
the GENCODE annotation version 3c, and then tested the model on newly annotated splice
junctions in the GENCODE annotation version 19. All GENCODE splice junctions used
for training and testing are experimental validated by RT-PCR amplification. The training
set contains 521,512 splice junctions, and the testing set contains 106,786 splice junctions.
In both training and testing sets, half of the splice junctions are annotated, and the rest are
false splice junctions randomly sampled from human reference genome (GRCh37/hg19).
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We trained the first model by feeding the 521,512 training splice junction sequences
to DeepSplice for a binary classification, splice junctions or not. In the meantime, we
trained two other models separately by feeding the donor (acceptor) splice site sequences
extracted from the 521,512 training splice junction sequences to DeepSplice for a binary
classification, donor (acceptor) splice sites or not. This experiment was designed to
determine whether making use of paired combinational information of donor and acceptor
splice sites from a splice junction, instead of classifying donor or acceptor splice site
individually, would ameliorate the quality of splice junction classification. In the first mode
(Splice Junction Mode), the input splice junction sequences were with the length of 120
nucleotides, reflecting 30 nucleotides of upstream and downstream nucleotides for both
donor and acceptor splice site. In the second mode (Donor+Acceptor Site Mode), the input
splice junction sequences were split into two substrings with the length of 60 nucleotides
and then fed to donor (acceptor) splice site classification model separately. For the second
mode, we defined that the probability of a splice junction being classified as positive is the
product of the probability of its donor splice site being classified as positive and the
probability of its acceptor splice site being classified as positive, considering the two splice
site classification events are statistically independent [73]. Figure 2.5 shows the ROC
curves of the two modes. Splice Junction Mode achieved an auPRC score of 0.990, 0.987
for Donor+Acceptor Site Mode. Table 2.2 summarizes sensitivity, specificity, accuracy,
and F1 score on the 106,786 testing splice junction sequences. Donor+Acceptor Site Mode
acquires a higher specificity; however, Splice Junction Mode significantly outperforms
Donor+Acceptor Site Mode in terms of sensitivity, accuracy, F1 score, auROC score, and
auPRC score with substantially higher scores. In total, Splice Junction Mode predicted
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50,340 out of 53,393 newly annotated splice junctions, which covered 9,806 genes, 98.01%
of all newly annotated genes. Donor+Acceptor Site Mode detected 39,067 splice junctions
from 9,185 genes. There is a 95% likelihood that the confidence interval [0.0432, 0.0456]
covers the true classification error of DeepSplice on the testing splice junctions. These
results indicate that the proposal splice junction classification in DeepSplice achieves high
accuracy in identifying novel splice junctions in large data sets than conventional splice
site classification.

Figure 2.5 The ROC curves of DeepSplice Splice Junction Mode and Donor+Acceptor
Site Mode for splice junction classification on the GENCODE data set. DeepSplice Splice
Junction Mode achieves a higher auROC score of 0.989.
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Table 2.2 Classification performance evaluation of different DeepSplice modes on
GENCODE data set
Splice site
classification
Splice
junction
classification

2.3.3

Sensitivity
Donor 0.917
Acceptor 0.873
Splice Junction Mode 0.943
Donor+Acceptor Site
0.732
Mode

Specificity
0.897
0.913
0.968

Accuracy
0.907
0.893
0.956

F1 score
0.908
0.891
0.955

0.997

0.864

0.844

Interpretation of sequence features captured by DeepSplice
There are highly conserved segments on splice junctions between exons and introns

which help in the prediction of splice junctions by computational methods and decipher
biological signals of splice junctions. We next further interpret which nucleotides
contribute to the splicing process. This is achieved by the quantification of the contribution
of nucleotides in splice junction sequences to the classification process using deep Taylor
decomposition [62].
DeepSplice employs convolutional neural network with two convolutional layers.
In the convolutional layer, we defined filters with a shape of 3x1, which means filters scan
the input sequence with a window size of 3 to learn the information of nucleotide
neighborhoods. DeepSplice fundamentally is not using a single base but rather 3-mers or
subsequences of length 3 as its features. Then deep Taylor decomposition runs a backward
pass on the convolutional neural network to sign contributions. The contribution score of
each single base in DeepSplice reflects the aggregated importance of the three 3-mers it
belongs to. We first used deep Taylor decomposition to decompose cross-validation results
of the HS3D dataset in terms of input splice site sequences. For nucleotides in the testing
splice site sequences, scores were assigned to present their contribution. We obtained a
graphical representation from which it is possible to judge which region in the splice site
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sequences is of importance. Figure 2.6 shows the contribution of nucleotides to the final
decision function of DeepSplice. In general, intron sequences carry more discriminative
information than exon sequences in this analysis. We then applied deep Taylor
decomposition to the results of splice junction classification with the GENCODE data set.
Figure 2.7 shows the contribution distribution of nucleotides in the testing splice junction
sequences. Regions of increased importance in splice junction classification are consistent
with the result from splice site classification.
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Figure 2.6 Visualization of the contribution of nucleotides in the flanking splice sequences
to the final decision function of DeepSplice on the HS3D dataset for donor (acceptor) site
classification. For both donor and acceptor site classifiers, intronic bases close to GT-AG
di-nucleotides achieve the most importance in the classifiers. In general, intron sequences
carry more discriminative information than exon sequences.
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Figure 2.7 Visualization of the contribution of nucleotides in the flanking splice sequences
to the final decision function of DeepSplice on the GENCODE dataset for splice junction
classification. The nucleotides in the proximity of a splice junction have the highest impact
on the classification outcome. As observed in the splice site classifiers, the contribution
distribution of nucleotides in the flanking splice sequences indicates that intron nucleotides
carry more discriminative information than exon nucleotides.

2.3.4

DeepSplice classification of intropolis
The intropolis v1 database [36] contains a large number of putative junctions found

across 21,504 human RNA-seq samples in the Sequence Read Archive (SRA) from spliced
read alignments to hg19 with Rail-RNA [37]. There are 42,882,032 putative splice
junctions in total, including 18,856,578 canonical splice junctions containing flanking
string GT-AG, 24,025,454 semi-canonical splice junctions containing flanking string ATAC or GC-AG [74], and no non-canonical splice junctions which are not allowed by RailRNA. Table 2.3 lists the number of splice junctions in each category separated by the
number of reoccurrence in samples and total read support across all samples in four scales:
(a) equal to 1 {1}, (b) more than 1 and no greater than 10 (1, 10], (c) more than 10 and no
greater than 1000 (10, 1000] and (d) more than 1000 (1000, +∞). As listed in Table 2.3, for
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our analysis, we only retain splice junctions in intropolis that are supported by more than
one sample, followed by the filtering of false splice junction sequences due to repetitive
sequences. After this pre-processing, 5,277,046 splice junctions were left for further
classification.

Table 2.3 Distribution of splice junctions from intropolis given the reoccurrence in
samples and total read support

Total reads

Splice junction
number

{1}
{1}
23M
(1, 10]
3,331K
(10, 1000]
91K
(1000, +∞) 38
“M” stands for “million”.
“K” stands for “thousand”.

Reoccurrence in samples
(1, 10] (10, 1000] (1000, +∞)
11M
936K
3,301K
187
124K
305K

The DeepSplice model was trained on 812,967 splice junctions including (1)
291,030 annotated splice junctions from GENCODE annotation version 19, (2) 271,937
false splice junctions generated from the HS3D data set, and (3) 250,000 randomly selected
semi-canonical splice junctions with only one read support from intropolis. Overall,
DeepSplice classified 3,063,698 splice junctions as positive. Figure 2.8 (a) lists the
proportions of positive canonical splice junctions, positive semi-canonical splice junctions
and negatives from the classification results at different levels of average read support per
sample. Splice junctions with average read support per sample more than 15 achieve a
positive rate around 88%. In contrast, for splice junctions with average read support per
sample no more than 1, only 36% are identified as positives. There is a significant rise in
the probability to obtain a positive splice junction with the increase of the average read
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support per sample. Around 99% positive splice junctions contain the canonical flanking
string. Figure 2.8 (b) illustrates the proportions of positive semi-canonical and canonical
splice junctions cumulatively with the increase of the average read support per sample.
To further clarify characteristics of the positives, we categorized splice junctions in
intropolis based on annotated splice sites in GENCODE annotation: (1) splice junctions
with both splice sites annotated, (2) splice junctions with the donor splice site annotated,
(3) splice junctions with the acceptor splice site annotated, and (4) splice junctions with
neither the donor nor acceptor splice sites annotated. Figure 2.9 (a) shows the discrete
proportions of negatives and positive splice junctions in each category above, given the
average read support per sample. Results indicate that 97% of splice junctions with both
sites annotated are classified as positives, while only 39% with both sites being novel are
positive. Splice junctions connecting annotated splice sites also tend to be associated with
higher read coverage. Figure 2.9 (b) illustrates the proportions of positive splice junctions
in each category cumulatively with the increase of the average read support per sample.
Figure 2.10 shows positive splice junctions in intropolis near known protein-coding
junctions show a periodic pattern, such that splice sites which maintain the coding frame
of the exon are observed more often than those which disrupt frame. This observation
recapitulates patterns seen in studies of noisy splicing [41].
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Figure 2.8 Positive splice junctions tend to have high read support and contain the
canonical flanking string. (a) Discrete proportions of negatives, positive semi-canonical
splice junctions and positive canonical splice junctions from the classification results,
given the average read support per sample. Splice junctions with average read support per
sample more than 15 achieve a positive rate of around 88%. In contrast, for splice junctions
with average read support per sample no more than 1, only 36% are identified as positive.
There is a significant rise in the probability to obtain a positive splice junction with the
increase of the average read support per sample. Around 99% positive splice junctions
contain the canonical flanking string. (b) Cumulative proportions of positive semicanonical and canonical splice junctions with the increase of the average read support per
sample.
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Figure 2.9 Positive splice junctions tend to have both donor and acceptor sites annotated.
(a) Discrete proportions of negatives, positive splice junctions without annotated site,
positive splice junctions with acceptor site annotated, positive splice junctions with donor
site annotated and positive splice junctions with two sides annotated, given the average
read support per sample. 97% of splice junctions with both sites annotated are classified as
positives, while only 39% with both sites being novel are positive. Splice junctions
connecting annotated splice sites also tend to be associated with higher read coverage. (b)
Cumulative proportions of positive splice junctions in each category with the increase of
the average read support per sample.
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Figure 2.10 Splice sites which maintain the coding frame of the exon are observed more
often than those which disrupt frame. Positive splice junctions in intropolis near known
protein-coding junctions show a periodic pattern. For each donor (acceptor) site in the
positive splice junctions, we calculated its distance to the nearest annotated donor
(acceptor) site, and then counted the frequency for each position. The red points denote
positions that are a multiple of three base pairs from the major splice form, and the black
points those that are not.

2.4

Summary
Even though splice junctions with high read support and/or high reoccurrence are

more likely to be classified as real, a significant portion of relatively low-expressed splice
junctions also carry true splicing signals. DeepSplice does not rely on sequencing read
support, frequency of occurrence, or sequencing read length derived from experimental
RNA-seq data sets, thus can be applied as an independent evidence for splice junction
validation. The accumulation of RNA-seq data especially in different cell types, tissues
and disease conditions will further consolidate the cell type-specificity and tissuespecificity of some of these junctions and their corresponding isoforms. DeepSplice may
provide the first round of filtering of RNA-seq derived splice junctions for further structural
validation, and studies that assess functional annotation of these splice junctions are
warranted. DeepSplice could also extend its functionality to discriminate splice junctions
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that are highly or lowly supported by gene expression evidence and try to figure out what
sequence patterns associate to this difference in future. For each input candidate splice
junction, DeepSplice outputs a probability of being true, and the probability can be used as
an input feature to the studies for learning the tissue-regulated splicing code [75] and the
splicing in human tissues with a wide range of known diseases [76].
It is also well known that splicing can be changed due to mutations around the
splice sites. Future studies that use subject-specific genomic sequences instead of reference
genome sequences may further improve the accuracy of the DeepSplice model and
classification performance. Additionally, DeepSplice can be further extended to the
prediction of non-canonical splicing [77] that existing annotation has not captured,
including not only exonic but also splicing involving Alu elements, small exons, and
recursive splicing. Besides the classification of linear junctions, the identification of nonlinear splice junctions, such as circRNA junctions will also expand the functionality of
DeepSplice.
Employing deep convolutional neural network, we develop DeepSplice, a model
inferred from the sequences of annotated exon junctions that can then classify splice
junctions derived from primary RNA-seq data, which can be applied to all species with
sufficient transcript annotation to use as training data. Results demonstrate that DeepSplice
outperforms the state-of-the-art splice site classification tools in terms of both classification
accuracy and computational efficiency. Our findings further indicate that valuable
information is present in the nucleotide sequence local to the splice junction, data that
conventional splice site prediction techniques discard. Nucleotide representations learned
from the input sequences are meaningful and improve accuracy. The major application of
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DeepSplice is the classification of splice junctions rather than individual donor or acceptor
sites. For learning on large datasets of putative splice junctions, DeepSplice is orders of
magnitude faster than the best performing existing alternatives, which becomes
increasingly common considering the tremendous amount of new RNA-seq data being
generated.
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CHAPTER 3. INFERRING TRANSCRIPTION FACTORS GOVERNING METABOLIC
REPROGRAMMING WITH TFMETA
Metabolic reprogramming is a hallmark of cancer. In cancer cells, transcription
factors (TFs) govern metabolic reprogramming through abnormally increasing or
decreasing the transcription rate of metabolic enzymes, which provides cancer cells growth
advantages and concurrently leads to the altered metabolic phenotypes observed in many
cancers. Consequently, targeting TFs that govern metabolic reprogramming can be highly
effective for novel cancer therapeutics. In this chapter, we present TFmeta, a machine
learning approach to uncover TFs that govern reprogramming of cancer metabolism. Our
approach achieves state-of-the-art performance in reconstructing interactions between TFs
and their target genes on public benchmark data sets. Leveraging TF binding profiles
inferred from genome-wide ChIP-seq experiments and 150 RNA-seq samples from 75
paired cancerous (CA) and non-cancerous (NC) human lung tissues, our approach
predicted 19 key TFs that may be the major regulators of the gene expression changes of
metabolic enzymes of the central metabolic pathway glycolysis, which may underlie the
dysregulation of glycolysis in non-small-cell lung cancer patients.

3.1

Introduction
Metabolism is collection of predominantly enzyme-catalyzed biochemical

transformations that are needed for maintenance, growth and survival of an organism. For
nearly a century, scientists have documented profound metabolic changes that occur in
tumors [78]. Oncogenes and tumor suppressors are well-established regulators of
metabolism, and dysregulated expression as well as mutations can lead to the altered
metabolic phenotypes observed in many cancers [79, 80]. A high proportion of oncogenes
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and tumor suppressor genes encode transcription factors (TFs) [81]. Most oncogenic
pathways converge on sets of TFs that ultimately control gene expression patterns resulting
in tumor formation and progression as well as metastasis [82]. Deregulated expression,
activation or inactivation of TFs play critical roles in tumorigenesis. In cancer cells, TFs
govern metabolic reprogramming by controlling the expression patterns of metabolic
enzymes. For example, the transcription factor MYC is frequently overexpressed in human
cancers and regulates the expression of many metabolic enzymes. In carcinomas, MYC
drives increased Gln uptake and conversion to Glu by upregulating glutamine transporters
and inducing the expression of metabolic enzyme GLS at the mRNA and protein level,
leading to increased anaplerotic input via glutaminolysis into the Krebs cycle and increased
Gln incorporation into lactate [79, 83, 84].
Comprehensive characterization of TF-metabolic enzyme interactions in cancer
cells can help uncover potential TFs governing cancer metabolic reprogramming and
prioritize targets for novel cancer therapeutics. Reconstructing interactions between TFs
and their target genes from transcriptomic data is a long-standing and well-studied
challenge in molecular and computational biology. Some interaction reconstruction
methods [85-88] exploiting co-expression in gene expression patterns have successfully
identified the interactions in the gene pairs whose expression vary sufficiently and correlate
globally across a large set of samples. Other methods [89, 90] take advantage of differential
gene expression to predict interactions between each TF and all the genes that are
differentially expressed when the TF is deleted, overexpressed or perturbed. These
methods, however, have at least two major drawbacks for reconstructing TF-target gene
interactions. First, a fundamental assumption of current interaction reconstruction methods
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using transcriptomic data is that mRNA levels of TFs and their target genes are strongly
correlated; however, this assumption may not be true for all the data sets, especially for
those containing complex TF-target gene interactions. The Dialogue on Reverse
Engineering Assessment and Methods (DREAM) project performed an assessment of 35
TF-target gene interaction reconstruction methods on both synthetic and real
transcriptomic data sets [85]. The competing methods achieved an average AUROC score
of 0.69 on the synthetic data set, but 0.55 on the real data sets. The poor performance on
the real data sets was due to the low correlation at the mRNA level in the data, which would
suggest that reliable reconstruction of complex TF-target gene interactions requires
additional inputs besides transcriptomic data, for example, TF binding profiles. Second,
current interaction reconstruction methods disregard the valuable pairing information of
the samples in transcriptomic data, treating each input gene expression profile
independently in their inference models. For cancer patients’ transcriptomic data, pairwise
comparisons of gene expression profiles between matched cancerous (CA) and noncancerous (NC) samples of the same patient should circumvent the interferences from
genetic and physiological variations, eliminating the prediction of false TF-target gene
interactions caused by the variations.
Here, we developed TFmeta [91], a machine learning method for the reverse
engineering of TF-metabolic enzyme interactions that pinpoint TFs governing cancer
metabolic reprogramming. TFmeta integrates transcriptomic data and TF binding profiles
inferred from genome-wide ChIP-seq experiments, to learn non-linear interactions between
TFs and their targets. Using a gold standard data set, namely DREAM5 network inference
challenge [85] data, we demonstrate that TFmeta outperformed the winner of the challenge
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in reconstructing TF-target gene interactions. Taking 150 RNA-seq samples from 75 paired
CA and NC human lung tissues and TF binding profiles as input, TFmeta predicted a set
of key TFs that may control the transcription rate of metabolic enzymes in the central
metabolic pathway glycolysis, which may cause the observed metabolic reprogramming in
glycolysis pathway in non-small-cell lung cancer patients [91].

3.2

3.2.1

TFmeta method

RNA-seq analysis
We sequenced 150 RNA-seq samples from 75 paired CA and NC human lung

tissues under IRB approval from the University of Kentucky. All patient information was
de-identified and adhered to HIPPA guidelines. 100 bp paired-end reads were generated
by Illumina HiSeq 2000 sequencer. RNA-seq reads were mapped to the human reference
genome GRCh38, and gene expression values (TPM, transcripts per million) were
estimated using RSEM package [92]. Gene expression profiles generated from RSEM were
normalized and comparable between samples. Pairwise gene expression comparisons of
CA and NA samples from the same patient were conducted through measuring the log2
ratios of gene expression values between CA and matched NC samples. Based on the log2
ratios, we maintained a master table for showing the regulation status of each gene in each
individual patient. The regulation status of each gene was represented by a categorical
variable that can take on one of the three possible values: upregulated, downregulated, and
no change. Genes with the |log2| ratio greater than 0.8 were categorized as upregulated (or
downregulated) genes, and the rest were genes with no expression change. The size of the
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master table was 19,814 (number of genes) by 75 (number of patients). Using the gene
expression log2 ratio of paired CA and NC tissue samples from the same patient should
reduce the effects of individuality and the impact of tissue-specific genes and consequently,
increase the accuracy of predicting clinical outcomes [93].
We then collected the detailed information of the major metabolic pathways in
human, including glycolysis, the Krebs cycle, purine metabolism, and others from KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathway database [94]. The regulation status
of metabolic enzymes involved in each metabolic pathways was extracted from the master
regulation status table. According to the one-tailed one-proportion z-test (with a
hypothesized proportion of 0.6667), we considered metabolic enzymes with consistent
expression change (upregulated or downregulated) among at least 57 patients out of the 75
patients as altered metabolic enzymes (p-value for 57 patients: p=0.0433<0.05).

3.2.2

Transcription factor binding profiling
We integrated TF binding profiles which were inferred from genome-wide ChIP-

seq experiments in four public databases, including ChEA [95], ENCODE [96], JASPAR
[97], TRANSFAC [98]. We eventually accumulated 2,286,192 TF DNA binding activities,
involving 493 TFs and 23,644 target genes. The minimum, median and maximum number
of TFs binding to a target gene is 1, 104 and 279, and the minimum, median and maximum
number of target genes for one TF is 4, 1853 and 21545, respectively. The total number of
metabolic enzymes involved in the major metabolic pathways is 366. For each altered
metabolic enzyme, we curated a list of TFs which bind to the transcription start site of that
enzyme according to the TF DNA binding activities.
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3.2.3

TF-metabolic enzyme interaction inference
Problem Definition

We approached the problem of uncovering TFs that govern

cancer metabolic reprogramming by measuring the interactions between the altered
metabolic enzymes and TFs binding to the transcription start sites of them. Through RNAseq analysis, we identified 𝑀 altered metabolic enzymes with consistent expression change
between CA and matched NC samples. We divided the problem of inferring TF-metabolic
enzyme interactions involving 𝑀 enzymes into 𝑀 sub-problems. Each of these subproblems uncovered the TFs regulating one of the enzymes. We generated 𝑀 sub-tables
from the master regulation status table, each of which contained the regulation status of
one enzyme and TFs which bind to the transcription start site of that enzyme according to
the TF DNA binding activities. In the sub-table, for enzyme 𝑚 with 𝑇𝑚 TFs binding to its
transcription start site, every patient’s regulation status profile can be expressed as
(x𝑛𝑚 , 𝑦𝑛𝑚 ), where 𝑛 ∈ {1, … , 𝑁} is the index of each patient out of 𝑁 patients, and x𝑛𝑚 is a
tensor of 𝑇𝑚 TF regulation status, and 𝑦𝑛𝑚 is the regulation status of enzyme 𝑚.
Interaction Inference as a Feature Selection Problem

TFs and their target genes

are known to interact in a dynamic and nonlinear manner [99]. We hypothesize that the
regulation status of the enzyme 𝑚 is a function 𝑓𝑚 of the regulation status of the 𝑇𝑚 TFs,
and the function 𝑓𝑚 only employs the regulation status of the TFs that are direct regulators
of the enzyme 𝑚. Identifying those TFs whose regulation status is predictive of the
regulation status of the enzyme 𝑚 can be considered as a feature selection problem, which
is to rank the input features in the function 𝑓𝑚 based on their relevance for predicting the
output in machine learning terminology. Considering a large amount of TFs as input
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features relative to a small set of learning patient regulation status profiles and the nonlinear
relationship between input TFs and the output enzyme, we proposed to use gradient
boosted trees [100, 101] to find the function 𝑓𝑚 and rank the input TFs by their relevance.
Gradient tree boosting is a scalable and highly effective machine learning algorithm, which
works well in reliably extracting relevant features and identifying non-linear feature
interactions.
Gradient Boosted Tree-based Model

For each sub-problem, we fitted a multi-

class classification model (𝑓𝑚 ) to predict the regulation status (upregulated, downregulated,
no change) of the enzyme 𝑚 based on the combined regulation status of the 𝑇𝑚 TFs.
Gradient boosted trees were employed to find the function 𝑓𝑚 which minimizes the multiclass classification error rate which is calculated as the number of wrong predictions
divided by the number of all predictions. To achieve this goal, classification and regression
tree (also known as CART) recursively partitions the 𝑁 patients into smaller disjoint sets
based on the input regulation status of TFs, aiming at minimizing the number of wrong
predictions of the output enzyme regulation status in the resulting subsets. Classification
and regression tree uses the tree structure to represent the recursive partition, and each of
the leaves in the tree represents a cell of partition. The basic idea of tree boosting is to build
additive models through classification and regression trees. Let 𝑏𝑚,𝑘 (x𝑛𝑚 ) be a
classification and regression tree in mth sub-problem, which works as the base learner. In
tree boosting, we built a model that is the sum of base learners as:
𝐾

𝑓𝑚 (x𝑛𝑚 ) = ∑ 𝑏𝑚,𝑘 (x𝑛𝑚 ),
𝑘=1

where 𝑘 ∈ {1, … , 𝐾} is the index of each base learner out of 𝐾 base learners. The target
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additive model was built in a forward stagewise fashion. Namely, it started with the simple
function 𝑓𝑚,0 (x𝑛𝑚 ) = 0, then iteratively adds base learners to minimize the multi-class
classification error rate of 𝑓𝑚,𝑘−1 (x𝑛𝑚 ) + 𝑏𝑚,𝑘 (x𝑛𝑚 ). Gradient Boosting attempts to solve
this minimization problem numerically via steepest descent. By iteratively shifting the
focus towards problematic observations that were difficult to predict, the performance of
the classification and regression tree is very much boosted.
Feature Importance Measure: TF Ranking

A benefit of using CART-based

methods is that after the trees are constructed, it is relatively straightforward to retrieve
estimates of feature importance that allow ranking the input features according to their
relevance for predicting the output. The importance is calculated for a single classification
and regression tree by the amount that each attribute split point reduces the Gini impurity,
weighted by the number of observations the node is responsible for. The feature importance
scores are then averaged across all the classification and regression trees within the model.
In this application, every CART-based sub-model solving one sub-problem yields a
separate ranking of TFs as potential regulators of a target enzyme 𝑚 along with importance
scores 𝐼𝑚,𝑡𝑚 for 𝑡𝑚 ∈ {1, … , 𝑇𝑚 }.
TF-metabolic enzyme Map

Our primary goal is ultimately using this approach

to find a relatively small number of robust target TFs based on multiple lines of evidence.
We considered a variety of strategies to select an appropriate threshold on the TF ranking
in each sub-model. For instance, we could apply an independent threshold for each submodel, or we could use a uniform threshold across all sub-models. We found that optimal
performance was obtained when we applied an overall threshold on the combined TF
ranking. To combine the separate rankings of TFs in sub-models, we performed the
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Wilcoxon signed-rank test on every pair of TFs to compare their ranks, which tested
whether the ranks of one TF from all sub-models were significantly higher (or lower) than
those of the other TF. Based on the test decisions of comparing all pairs of TFs, the orders
of TFs were eventually determined to generate the combined ranking. Through evaluating
the number of output TFs and their biological significance, we considered TFs in the top
5% of the combined ranking as robust targets. The interactions between the predicted TFs
and their target enzymes were then displayed in a TF-metabolic enzyme map. The overall
workflow of TF-metabolic enzyme interaction inference is shown in Figure 3.1.
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Figure 3.1 Overview of TF-metabolic enzyme interaction inference workflow. We divided
the problem of inferring TF-metabolic enzyme interactions involving 𝑀 enzymes into 𝑀
sub-problems. In each sub-problem, taking the regulation status table of one enzyme and
TFs binding to its transcription start site as input, we utilized gradient boosted trees to
identify those TFs whose regulation status is predictive of the regulation status of the
enzyme. This learning process was repeated on all the 𝑀 enzymes. The predicted
interactions between TFs and enzymes were then displayed in the TF-metabolic enzyme
map as output.

3.2.4

Implementation
TFmeta was implemented using scikit-learn library (version 0.19.1) [102] and

XGBoost library (version 0.7) [101] in Python (version 2.7.13) as task parallelized
program. TFmeta [91] is freely available for academic use and can be accessible at
https://github.com/zhangyimc/TFmeta.
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3.3

3.3.1

Experimental results

Benchmarking TFmeta with DREAM5 Network Inference Challenge data sets
We utilized the data sets in Dialogue on Reverse Engineering Assessment and

Methods (DREAM) 5 network inference challenge [85]. The DREAM project is a
framework to enable an assessment of computational methods through standardized
performance metrics and common benchmarks. DREAM5 challenge performed a
comprehensive blind assessment of 35 TF-target gene interaction inference methods on
Escherichia coli, Staphylococcus aureus, Saccharomyces cerevisiae and in silico
microarray data. Table 3.1 summarizes the number of TFs, the number of genes, and the
number of microarray chips for each network. DREAM5 challenge organizer claimed that
Staphylococcus aureus data was not used for the final evaluation for the lack of a
sufficiently large set of experimentally validated interactions. Each microarray data set is
represented as a 𝑚 ∗ 𝑛 gene expression matrix, where 𝑚 is the total number of genes
including both TFs and target genes, and 𝑛 is the total number of microarray measurements.
Based on descriptions provided by participants, DREAM5 challenge classified the 35
competing methods into six distinct categories: regression, mutual information, correlation,
Bayesian networks, meta (methods that combine several different approaches) and others
(methods that do not belong to any of the previous categories).

51

Table 3.1 Summary of DREAM5 Challenge Data Sets
Network
In silico
S.aureus
E. coli
S. cerevisiae

Number
of TFs
195
99
334
333

Number
of genes
1643
2810
4511
5950

Number of
microarray chips
805
160
805
536

TFmeta was trained and tested on the same benchmark data sets used by the 35
competing methods. Since the input data is numerical, the gene expression values
generated from microarray chips, the functionality of classification and regression trees
(CART) in TFmeta was shifted from classification to regression. In DREAM5 challenge,
standardized performance metrics were provided to evaluate the performance of different
methods. An overall score was used to summarize the performance across the three
networks, which is a comprehensive assessment on both the area under the precision-recall
(AUPR) and receiver operating characteristic (AUROC) curves. We applied the same
metrics used by the 35 competing methods to TFmeta. Figure 3.2 (a) shows the overall
scores for TFmeta and the 35 competing methods. The winner of DREAM5 challenge,
GENIE3 [88], achieved an overall score of 40.279. The overall score of TFmeta is 69.031,
which outperforms the winner of DREAM5 challenge.
Transcription-factor perturbation experiments can be applied to validate the
biological significance of the TFs predicted by computational methods. However, the usage
of transcription-factor perturbation experiments is limited by their high cost and strong
dependence on cellular type and context. Though TF-target gene interaction inference
methods reconstruct gene regulatory networks with a large set of regulatory interactions,
the number of TFs chosen for further experimental validation is always limited, and it is
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highly likely that only the top predicted interactions will be selected for further validation.
We then evaluated the accuracy of the top interactions predicted by GENIE3 and TFmeta.
As shown in Figure 3.2 (b), TFmeta consistently achieved a higher accuracy than GENIE3
for the top predictions on in silico data set, indicating that the most significant interactions
predicted by TFmeta are more likely to be true interactions than those by GENIE3. We
further compared TFmeta with GENIE3 in terms of computational efficiency. Figure 3.2
(c) illustrates the total CPU running time of GENIE3 and TFmeta for reconstructing the
testing gene regulatory networks. It took GENIE3 761.58 hours to finish the entire
reconstruction job, but only 6.03 hours for TFmeta. TFmeta is orders of magnitude faster
than GENIE3.
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Figure 3.2 Performance evaluation of DREAM5 challenge data sets. (a) demonstrates the
overall scores for TFmeta and the 35 competing methods. The winner of DREAM5
challenge, GENIE3, achieved an overall score of 40.279. The overall score of TFmeta is
69.031. (b) illustrates the accuracy of the top interactions predicted by GENIE3 and
TFmeta. TFmeta consistently achieved a higher accuracy than GENIE3. (c) shows the total
CPU running time of GENIE3 and TFmeta on the testing datasets. TFmeta is orders of
magnitude faster than GENIE3.

3.3.2

Prediction of TFs governing the dysregulation of glycolysis in NSCLC patients
All parts of the body require energy to maintain non-equilibrium cellular states and

perform work, and this energy is derived from consumption and oxidation of external
nutrients. Typically, all food is broken down into smaller parts and coupled to the
production of the main energy intermediate, ATP. ATP provides a uniformly usable store
of biochemical energy that can be used to drive endergonic cellular reactions. The process
of the breakdown of glucose, termed glycolysis, occurs in the cytoplasm of mammalian
cells [103]. Since the early twentieth century, abnormalities of glycolysis in cancer cells
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have been observed [104]. Marked progress has been made in understanding the molecular
mechanisms leading to constitutive upregulation of glycolysis in tumor cells. Many
glycolytic enzymes are often overexpressed in

cancer cells.

For example,

phosphofructokinase-1 (PFK1) has been identified to be upregulated in types of breast
cancer [105]. Another well-known classic glycolytic enzyme, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) is also implicated in cancer. Overexpression of GAPDH is
considered an important feature of numerous types of cancer [103]. GAPDH has been
proposed as a promising target for the treatment of carcinomas [106]. Both MYC and
HIF1a are known to upregulate expression of most of the glycolytic enzymes in cancers
[107]. These results indicate that uncovering TFs that govern the abnormal expression
patterns of these glycolysis and/or glycolytic enzymes in tumor cells may underlie the
abnormalities of glycolysis, which could be highly effective for the treatment of different
types of cancer.
We acquired 150 RNA-seq samples from 75 paired CA and NC human lung tissues.
Through pairwise gene expression comparisons of CA and NA samples from the same
patient, we identified 14 altered glycolytic enzymes with consistent expression changes.
ENO1, ENO2, GAPDH, GPI, LDHA, PFKP, PKM, and TPI1 were upregulated, whereas
ACSS2, ADH1B, ALDH2, ALDH3B1, FBP1, and HK3 were downregulated. Using a
network editor, Omix [108], we visualized the patient-specific regulation status of part of
glycolytic enzymes in four selected patients (UK022, UK059, UK084, and UK085) in the
context of glycolysis pathway extracted from KEGG [94] pathway database, as shown in
Figure 3.3. Each pie chart in Figure 3.3 depicts the regulation status of one enzyme in one
patient. The pie chart with a larger slice of red (white) indicates the upregulation

55

(downregulation) of the enzyme. Though they are all non-small-cell lung cancer patients,
individual differences in the regulation status of some enzymes can be observed. In the
meanwhile, some well-known glycolytic enzyme, like PFKP, GAPDH, and PKM, are
consistently upregulated in the four patients. This pairwise comparison analysis and
patient-specific visualization eliminated the interferences from genetic and physiological
variations, and also characterized the difference and consistency in regulation status among
the patients.
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Figure 3.3 Visualization of the regulation status of part of glycolytic enzymes in the
context of glycolysis pathway. We randomly selected four patients: UK022, UK059,
UK084 and UK085 (from left to right). Each pie chart in the figure illustrates the regulation
status of one enzyme in one patient. The pie chart with a larger slice of red (white) indicates
the upregulation (downregulation) of the enzyme. Individual differences in the regulation
status of some enzymes can be observed among the four patients. Meanwhile, some wellknown glycolytic enzymes, like PFKP, GAPDH, and PKM, are consistently upregulated
in the four patients. In total, twelve (three) out of thirty-five enzymes shown in the figure
are consistently upregulated (downregulated) in the four patients. Glycolytic enzymes are
more likely to be overexpressed in cancer cells.

For every altered glycolytic enzyme, we curated a list of TFs which bind to the
transcription start site of that enzyme according. to the TF DNA binding activities inferred
from ChIP-seq experiments. The average number of TFs selected for one enzyme is 134.
We then fitted a gradient boosted tree-based classification model to predict the regulation
status of each altered glycolytic enzyme based on the combined regulation status of the
selected TFs. The optimal model configuration was achieved by extensive hyperparameter
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search over various learning rate (0.001, 0.01, 0.1, and 1), maximum tree depth (1, 3, and
5), and number of rounds for boosting (100, 200, 300, and 400). To evaluate the
performance of models with different parameter settings, 10-fold cross-validation was
used. Table 3.2 summarizes the average prediction accuracy of models varying parameter
settings upon the 14 altered glycolytic enzymes. Based on this results, we used 0.01 as
learning rate, 3 as maximum tree depth, and 300 as number of rounds for boosting in our
model to save the computing time without loss of classification accuracy.

Table 3.2 Performance evaluation of models with different parameter settings
Learning rate

Maximum
tree depth

0.001
0.01
0.1
1

3

0.01

1
3
5

0.01

3

Number of rounds
Accuracy
for boosting
0.696
0.723
300
0.661
0.634
0.714
300
0.723
0.723
100
0.679
200
0.714
300
0.723
400
0.705

The application of TFmeta allows us to narrow down to a list of key TFs as
modulating the dysregulated expression of those altered glycolytic enzymes. Figure 3.4
shows the TF-metabolic enzyme map predicted by TFmeta. In the map, the 14 altered
glycolytic enzymes (red squares) and 19 predicted TFs (blue squares) are nodes, and an
edge from one TF to one enzyme demonstrates that TF is predicted to regulate that enzyme,
and all the edges are directed. Some predicted TFs and their interactions with glycolytic
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enzymes in the map have already been supported by literature evidence. For example,
transcription factor E2-alpha (TCF3) was identified as novel putative TF in lung cancer
[109]. ETS Proto-Oncogene 1 (ETS1) was reported as a key TF involved in the metabolism
of cancer cells, and ETS1 is particularly important in the metabolic shift towards glycolysis
and anabolic means of energy production [110]. Enhancer of zeste homolog 2 (EZH2)
promotes tumorigenesis and malignant progression in part by activating glycolysis. The
mRNA expression of key enzymes involved in glycolysis in xenograft tumors was
significantly increased in tumors derived from cells overexpressing EZH2, which suggests
EZH2 overexpression leads to increases in glycolysis in vivo [111]. Forkhead box
transcription factor-2 (FOXA2) was implicated as a suppressor of lung cancer, playing an
important role in lipid and glucose metabolism in lung development using Foxa2+/– mice
model [112]. Another well-known TF, MYC is a critical growth regulatory gene that is
commonly overexpressed in a wide range of cancers. Overexpression of MYC leads to the
upregulation of many glycolytic enzymes [113]. Zinc finger and BTB domain-containing
protein 7A (ZBTB7A) acts as a tumor suppressor through the transcriptional repression of
glycolysis, which directly binds to the promoter and represses the transcription of critical
glycolytic enzymes, including GLUT3, PFKP, and PKM [114]. Krüppel-like factor 4
(KLF4) represses the transcription of the glycolytic enzyme LDHA in pancreatic cancer
[115]. We propose that these TFs should be prioritized for follow-up experiments, both to
validate predicted target metabolic enzymes and to evaluate specific biological functions
for each TF. We further visualized the regulation status of 8 well-known classic glycolytic
enzymes and 2 predicted TFs, KLF4 (known as a tumor suppressor gene in lung cancer)
and EZH2 (known as an oncogene), in the 75 patients, as shown in Figure 3.5. The
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regulation status of EZH2 and the 8 enzymes are positively correlated, on the contrary,
KLF4 is negatively correlated with the 8 enzymes in terms of regulation status.

Figure 3.4 Visualization of the TF-metabolic enzyme map predicted by TFmeta. In the
map, the 14 altered glycolytic enzymes (red squares) and 19 predicted TFs (blue squares)
are nodes, and an edge from one TF to one enzyme demonstrates that TF is predicted to
regulate that enzyme, and all the edges are directed.

Thus, in this pilot study, we demonstrated the feasibility of using TFmeta for
uncovering TFs that govern glycolytic reprogramming in non-small-cell lung cancer
patients. This approach should be equally powerful for deciphering other metabolic
reprogramming in cancer cells, thereby enabling more comprehensive characterization of
cancer metabolism.
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Figure 3.5 Heatmap of the regulation status of 8 well-known classic glycolytic enzymes
and 2 predicted TFs, KLF4 and EZH2, in the 75 patients. The regulation status of EZH2
and the 8 enzymes are positively correlated, on the contrary, KLF4 is negatively correlated
with the 8 enzymes in terms of regulation status. EZH2 is known as an oncogene, and
KLF4 is a tumor suppressor gene in lung cancer.

3.3.3

Prediction of TFs governing other major metabolic pathways in NSCLC patients
We further applied TFmeta to infer TFs that govern other major metabolic

pathways in non-small-cell lung cancer patients. The Krebs cycle is a central metabolic
hub that integrates carbohydrate, lipid, and amino acid metabolism. The pentose phosphate
pathway (PPP) is an alternative route for glycolysis, yielding ribose 5-phosphate for
nucleotide biosynthesis and NADPH for fatty acid biosynthesis and decomposition of
peroxides [116]. Purine metabolism maintains cellular pools of adenylate and guanylate
via synthesis and degradation of purine nucleotides. The top TFs predicted for each
metabolic pathway are shown as follows:
a) The Krebs cycle: ZBTB7A, MYC, SMARCB1, TAL1, TCF7L2;
b) The pentose phosphate pathway: FOXA2, MYC, EGR1, TCF3, ZEB1;
c) Purine metabolism: MYC, H2AFZ, EZH2, NFIC, ETS1, TCF3, BHLHE40,
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CEBPB, STAT1, MAFK.

3.4

Summary
Metabolic reprogramming of cancer cells is recognized as one of the hallmarks of

cancer. Tumors remarkably elevate the expression of the majority of metabolic enzymes,
which play active roles in promoting cancer survival, metastasis, and invasion. One of the
most common trends in anti-cancer metabolism therapies is to inhibit metabolic enzymes
that are exclusively or mostly expressed or used in tumor cells. This therapeutic strategy
would effectively eliminate tumors while minimizing damage to normal cells [117]. Thus,
targeting TFs that control the transcription rate of those metabolic enzymes could be highly
effective for novel cancer therapy.
In this work, we develop TFmeta, a machine learning approach to uncover TFs
governing cancer metabolic reprogramming and reconstruct their interactions with metabolic
enzymes. We demonstrated that TFmeta achieved state-of-the-art performance in recovering
TF-target gene interactions on public benchmark data sets. We applied our model to nonsmall-cell lung cancer patients’ data sets to predict TFs modulating the dysregulation of
glycolysis in lung cancer, leveraging the pairing information of the samples and TF DNA
binding activities that conventional approaches discard. Eventually, we predicted a list of key
TFs that may motivate the upregulation of glycolysis observed in tumor cells, some of which
have been supported by literature evidence, and some of which were predicted as novel
putative TFs in lung cancer. Our model can also be easily deployed to uncover TFs governing
other metabolic pathways, in addition to glycolysis.
Based on our results, we found the majority of metabolic enzymes have interactions
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with more than one TFs. TFs are known to have to work together to achieve needed
specificity in both DNA binding and effector function [118]. In our current model, the
analysis of TF-TF relationships is generally lacking. TFmeta could extend its functionality
to evaluate the associations of TFs in future.
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CHAPTER 4. WHOLE MAMMOGRAM IMAGE CLASSIFICATION WITH CONVOLUTIONAL
NEURAL NETWORKS

Due to the high variability in tumor morphology and the low signal-to-noise ratio
inherent to mammography, manual classification of mammogram and tomosynthesis yields
a significant number of patients being called back, and subsequent large number of biopsies
performed to reduce the risk of missing cancer. The convolutional neural network (CNN)
is a popular deep learning construct used in image classification. This technique has
achieved significant advancements in large-set image-classification challenges in recent
years. In this study, we had obtained over 3000 high-quality original mammograms and
tomosynthesis with approval from an institutional review board at the University of
Kentucky. Different classifiers based on CNNs were built to classify both the 2D
mammograms and 3D tomosynthesis, and each classifier was evaluated based on its
performance relative to truth values generated by histology results from biopsy and twoyear negative mammogram follow-up confirmed by expert radiologists. Our results
showed that CNN model we had built and optimized via data augmentation and transfer
learning have a great potential for automatic breast cancer detection using mammograms
and tomosynthesis.

4.1

Introduction
Breast cancer is the most common cancer in women. Approximately 40,000 breast

cancer patients die each year in the U.S [119]. Early detection of cancer significantly
reduces the death rate [120]. To find breast cancer in early stages, before patients exhibit
symptoms, women are recommended to undergo a screening test, commonly a
mammogram. Mammography entails exposing a patient’s breasts to low levels of X-ray
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radiation. Breast cancer are identifiable from mammograms thanks to the different X-ray
absorption rates of normal and abnormal tissues. Tumors can appear as masses, distortions
or micro-calcifications on mammograms [121]. In patient with dense breast tissue, the
tumor mass may overlap with the dense tissue, creating masking effect and making
mammography less sensitive. Breast tomosynthesis is a newly emerging breast imaging
technique first approved by the FDA in 2011. It takes multiple X-ray images at different
angles; the images are then reconstructed to yield a video from which a radiologist can
identify abnormalities. Compared to traditional mammograms, tomosynthesis provides
more accurate results because tumors can be more easily distinguished from dense tissues
using images taken from different angles [122]. Normally, mammograms and
tomosynthesis were acquired in two standard orientations: Craniocaudal (CC) and Mediallateral-oblique (MLO) views during screening. Figure 4.1 shows an example of the CC and
MLO views of mammogram of two breasts, and Figure 4.2 shows an example of the
multiple slices of the right CC view of tomosynthesis from the same patient.

Figure 4.1 Illustration of 2D mammogram (from left to right): right CC view, left CC view,
right MLO, left MLO view.
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Figure 4.2 Illustration of 3D tomosynthesis: multiple slices of right CC view.

Screening mammography is the only imaging modality that has been proven to
reduce breast cancer mortality [123]. However, mammography is also associated with high
recall rates and high false-positive results [124]. With current practice, approximately 10%
of all women screened for breast cancer are called back for additional work-ups, but only
0.5% are diagnosed with breast cancer (that is, 5 cancer detected out of 1,000 women
screened, or 5 out of the 100 women called back). The use of the new technology,
tomosynthesis in conjunction with mammography, was showed to improve the accuracy of
cancer detection [125]. However, manual classification by radiologists still incurs a high
recall rate and requires years of experience on the part of the radiologist. This high recall
rate results in an abundance of additional diagnostic tests, including biopsy, and thus
contributes to increased health-care costs as well as unnecessary emotional turmoil for the
patients themselves [121, 126, 127].
Deep learning with convolutional neural networks has emerged as one of the most
powerful machine-learning tools in image classification, surpassing the accuracy of almost
all other traditional classification methods and even human ability [128]. The convolutional
process can simplify an image containing millions of pixels to a set of small feature maps,
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thereby reducing the dimension of input data while retaining the most important differential
features. The application of CNNs to classify mammograms is not entirely new. However,
most of the work focus on the classification of small patches, referred to as region of
interest (ROI) [129]. An ROI is the region that is likely to contain a tumor. This is typically
carved out of the whole images based on either clinical information or automatic
segmentation. Daniel Lévy et al. used deep CNNs on small patches of mammograms,
achieving a maximum accuracy of 93% [130]. Neeraj Dhungel et al. built a deep learning
based method that automatically segments the area of lesions and then classifies the
mammogram. Their best results were 0.74 for whole image, 0.8 for whole image plus
automatically detected small lession patches, and 0.91 for whole image plus manually
segmented small patches in terms of auROC [131]. In general, the classification of
mammograms using small abnormality patches affords reasonable performance but
requires very extensive pre-processing work.
An effective classification model for whole mammograms would offer multiple
benefits, including (a) saving the work of annotating partial mammograms and its
associated segmentation errors, (b) optimizing the use of contextual information
surrounding tumors, (c) closely representing the real-world clinical practice, and (d)
reducing the patient call-back rate, and thus the number of unnecessary tests conducted,
without harming sensitivity. However, classification with whole images is much more
challenging than with small patches due to the increased size and feature space. The best
performance reported on whole mammography classification with CNN is 60.90% in terms
of accuracy by Henry Zhou et al [132].
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In this work, we developed and evaluated a number of CNN models for wholemammography image classification [133]. We also present the first breast cancer
classification model using 3D tomosynthesis data, a relatively new technology that is only
available to 20% of major hospitals in the US. All images were collected at the Department
of Radiology, University of Kentucky with an institutional review board approval (IRB170011-P3K). Techniques including data augmentation [134] and transfer learning [135] are
combined with CNN models to optimize the performance of the classifiers.

4.2

Architecture overview
Our approach employs deep convolutional neural networks to classify whole-

mammography images from both the 2D mammograms and 3D tomosynthesis data. The
pipeline consists of three stages: data augmentation, transfer learning and CNNs. Ten
different models in total were developed, optimized and compared through cross validation
[136].

4.2.1

Data augmentation
Generally, deep neural networks require training on a large number of training

samples to perform well. However, biomedical datasets like ours contain a relatively small
number of samples due to limited patient volume. Data augmentation is a method for
increasing the size of input data by generating new data from the original input data. Many
strategies exist for image data augmentation [5, 128]. This study employed a combination
of reflection and rotation. For the 2D mammograms, each original image was flipped
horizontally. The original and reflected images were then rotated by each of 90, 180, and
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270 degrees. Each original image was thus augmented to eight images. For each
tomosynthesis sample, the 3D image sequences as a whole were either horizontally flipped
or not flipped, and then randomly rotated 0, 90, 180 or 270 degrees. Such data
augmentation generates relevant training samples because tumors may present themselves
in various orientations.
The data augmentation can be performed either before the training or during
training. Frontloading the augmentation process reduces the running time of the tests but
requires 8 times more disk space to store all images. While this is applicable for 2D images,
for the 3D tomosynthesis data, data augmentation was performed during the training phase
to minimize storage usage.

4.2.2

Transfer learning
Transfer learning is the re-use of information obtained during the training phase of

a previous project. In the field of image classification, the CNNs [128] trained in the course
of successful projects are sometimes published for use by other researchers. Two popular
transfer-learning methods involve (a) fine-tuning the parameters in certain layers of the
trained CNN, or (b) using the trained CNN to calculate the feature maps of new types of
data.
Mammography data is different from natural image data due to its limited color
distribution and structures. However, it can still leverage the basic image features in terms
of edges and shapes that can be soundly detected by well-trained CNN models. This study
utilizes AlexNet [128], trained with ImageNet [137]. Considering the fact that
mammograms differ dramatically from the images in the ImageNet dataset, the trained
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AlexNet was used only to obtain the feature maps. Each image in the augmented dataset
was resized to 832*832, which resolution was chosen with the goal of retaining tumor pixel
information. The ImageNet trained AlexNet was deployed to generate the feature maps for
the resized images. AlexNet output the feature maps with the shape of 25*25*256. The
feature maps were then used in the training of the following shallow CNNs.

4.2.3

CNN architectures
We have built different architectures of convolutional neural networks to classify

the 2D mammograms and 3D tomosynthesis images. A general shallow CNN architecture
is shown in Figure 4.3. Each convolution layer (Conv layer) includes convolution, batch
normalization [138], leaky ReLU [139] and max pooling [128]. All CNNs used Max
pooling with stride 2. The optimizer used is the Adam optimizer [65]. L2 regularization
was introduced in the loss function to prevent overfitting [66]. Dropout was also included
to improve the model performance [67]. We also adopted two top-performing CNN
architectures, AlexNet [128] and ResNet50 [140], to classify the 2D whole mammograms.
Additionally, we have built several models incorporating transfer learning with feature
maps learned from AlexNet. Detailed mathematical description of each step is omitted in
this paper as they are well established deep learning techniques.
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Figure 4.3 Sample convolutional neural network architecture used in this study. Conv layer
denotes the convolution, batch normalization, leaky ReLU and max pooling process. Conv
layers are followed by fully connected layers (Fully conn) and output layer.

The complete list of architectures is provided in Table 4.1. During the training
phase, learning rate, dropout and L2 regularization beta were tuned with the range of
0.0001 to 0.1, 0.25 to 1 and 0.00001 to 0.1 respectively. The learning rate decay rate of
Adam optimizer was set to 0.985 based on the preliminary results. The batch size was set
by two rules: (1) power of two and (2) largest data size can fit the 8 GB memory.

Table 4.1 Detailed architectures of tested models for 2D mammogram and 3D
tomosynthesis classification
Architecture
2D-A1
2D-A2
AlexNet
ResNet50
2D-T1-Alex
2D-T2-Alex
2D-T3-Alex
3D-A1
3D-T1-Alex
3D-T2-Alex

Transfer
Learning
No
No
No
No
Yes
Yes
Yes
No
Yes
Yes

Input Shape

conv1

conv2

conv3

fc1

fc2

Output

224*224*3
224*224*3
224*224*3
224*224*3
25*25*256
25*25*256
25*25*256
128*128*16*3
25*25*16*256
25*25*16*256

6@5*5
16@3*3
--256@1*1
256@1*1
256@1*1
16@3*3*3
32@3*3*3
256@1*1*1

16@3*3
32@3*3
-----32@3*3*3
---

-64@3*3
-----64@3*3*3
---

1024
1024
--1024
1024
512
1024
256
256

1024
1024
---1024
512
1024
256
256

2
2
2
2
2
2
2
2
2
2

Imbalanced data represent a common problem in machine-learning projects [141].
If imbalances in the training data are not considered, the resulting model generally
performs well on the larger class but poorly on the smaller class. The target dataset for this
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study was classically imbalanced, with roughly 90% of samples representing negative
diagnoses. To reduce the imbalance effect, the mini-batches [138] selected during the
training phase were restricted to be balanced. During each training epoch, the training data
were randomly split into m folds:
m=

Npos
n/2

where Npos denotes the number of positive samples (smaller class) in the training set, and
n is the batch size. In each iteration, all positive samples (n/2 samples) and n/2 randomly
selected negative samples of 1-fold training data were fed to train the CNN.
For the data input, 2D mammograms and their feature maps were read as three
dimensional tensors with shape defined as length*width*channels. 3D tomosynthesis data
and their feature maps were read as four dimensional tensors with shape defined as
length*width*depth*channels. Here, depth denotes the number of frames of 3D
tomosynthesis data, which may vary across tomosynthesis samples. To obtain a fixed input
shape, an equal number of frames were selected for each sample. Selected frames were
start from frame 0 and with equal interval in one tomosynthesis sample. In this study, the
frame number was set to 16 to fit the hardware limitation.

4.2.4

Implementation and performance evaluation
The convolutional neural networks were implemented using TensorFlow [70]. All

the tests were performed on a machine with two groups of four Nvidia GTX 1080 GPUs,
each with 8 GB memory.
To evaluate the performance of each prediction model, cross validation was used.
The dataset was randomly partitioned into training and testing datasets. The training set
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was used to train the model; the results of predictions made on the testing set were used to
evaluate the performance of the model. The training-testing ratio used in all validation tests
was 4:1.
Receiver operating characteristic curve (ROC) [142] is plotted as the true-positive
rate versus the false-positive rate at various thresholds. The area under the ROC curve,
auROC is used to measure the performance of a binary classifier. Tradeoffs can be made
based on ROC curves to select the most appropriate classification model. When testing the
prediction models in this study, probability of all test samples in each class was calculated.
Using each value in the probability set as the threshold, we can derive true-positive rates
(TPRs) and false-positive rates (FPRs). These TPR-FPR data were then used to plot the
ROC curve and calculate the auROC.

4.3

4.3.1

Experimental results

Data description
High-quality mammogram data from the University of Kentucky Medical Center

were obtained with institutional review board approval (IRB 17-0011-P3K). All
mammography images were assessed by experienced radiologists. The dataset includes
3,018 negative and 272 positive mammogram images. Each of the positive image contains
at least one biopsy-proven malignant tumor. The negative images do not contain malignant
tumors confirmed with at least 2- year negative mammogram follow-up assessed by
radiologists, but may have benign masses approved by biopsy or established more than 2 year imaging stability. All exams in the dataset were taken in either CC or MLO view or
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both. Negative images originated from 793 patients, most of which had 4 images taken:
namely, CC and MLO views for both left and right breasts. Positive samples originated
from 125 patients. Most positive patients have two images collected: CC and MLO views
of the breast site with tumor. For each exam, both 2D mammogram and 3D tomosynthesis
results were obtained. The 2D mammograms were provided in 12-bit DICOM format at
3328*4096 resolution. The 3D tomosynthesis images were provided in 8-bit AVI format
with a resolution of 768*1024. Table 4.2 summarizes the dataset used in this study. All
data were de-identified to protect the patients’ privacy. In order to save storage space and
reduce the time of file I/O, the pixel array for each 2D mammogram DICOM file was saved
as a 16-bit JPEG image. For each 3D tomosynthesis AVI file, all frames were processed to
a set of 8-bit JPEG images for the same purpose. The total number of frames for each 3D
tomosynthesis exam varies from 21 to 120.

Table 4.2 2D mammogram and 3D tomosynthesis data used in this study
View
RCC
RMLO
LCC
LMLO
Total

4.3.2

Negatives
758
759
751
750
3018

Positives
77
73
64
58
272

Effect of data augmentation
Data augmentation increases the size of the training dataset 8-fold. It significantly

improves the performance of almost every CNN architecture tested by roughly 0.1 auROC
units. Figure 4.4 (A) and (B) depicts the training loss status of architecture 2D-T2 without
and with data augmentation and Figure 4.4 (C) shows the associated ROC curves. The
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auROC of the test with data augmentation is 0.73 comparing to 0.62 for the test without
data augmentation. The training loss converged more smoothly with data augmentation
than without. For this reason, all subsequent tests utilized the data augmentation strategy.

Figure 4.4 Loss converge status of tests using data without (a) and with augmentation (b)
and ROC curves of them (c).
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4.3.3

2D mammogram classification
We evaluated all CNN architectures on 2D mammography images listed in Table

4.1. The loss converge status during the training phase of all those architectures were
shown in Figure 4.5. The optimized parameter combination and results of the best shallowCNN model, the best classic-CNN model, and the best transfer-learning model for 2D
mammograms are summarized in Table 4.3.
While classic-CNN models such as AlexNet do generate competitive results, the
best architecture seems to be the one leveraging transfer-learning where feature maps
derived from ImageNet-trained AlexNet are used for training. For example, 2D-T2-Alex
delivers the best auROC approaching 0.73. The result suggests that utilizing the pre-trained
model can be more sensitive in detecting key elements such as edges and shapes within a
mammogram image as well. However, due to inherent difference between mammogram
image and natural images, further training with these features using even a shallow CNN
still delivers better classification accuracy than using AlexNet alone.
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Figure 4.5 Loss converge status of 2D mammogram classification models: (a) 2D-A1, (b)
2D-A2, (c) AlexNet, (d) ResNet50, (e) 2D-T1-Alex, (f) 2D-T2-Alex, (g) 2D-T3-Alex. (h)
illustrates the ROC curves of different models.
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Table 4.3 Validation results and optimized parameter combination of 2D mammogram
classification models
Architecture
2D-A1
2D-A2
AlexNet
ResNet50
2D-T1-Alex
2D-T2-Alex
2D-T3-Alex

4.3.4

Batch Learning
L2 regularization
Dropout
auROC
size
rate
beta
128
0.1
0.5
0.001
0.5488
128
0.1
1
0.001
0.6295
128
0.0001
0.25
0.001
0.6749
32
0.01
0.5
0.001
0.6239
256
0.0001
0.5
0.0001
0.7234
256
0.001
0.5
0.0001
0.7274
256
0.001
0.5
0.01
0.7237

3D tomosynthesis classification
We also evaluated three architectures listed in Table 4.1 designed for 3D

tomosynthesis images. Cross validation was used to test one model, 3D-A1, on 3D
tomosynthesis data, and two models on 3D tomosynthesis feature maps derived from
transfer learning. The loss converge status during the training phase of all 3D classification
architectures were shown in Figure 4.6. The optimized parameters and auROCs for the
three models are shown in Table 4.4. Based on the tests, 3D-T2-Alex exhibited the best
performance on 3D tomosynthesis feature maps; similar to 2D images, transfer learning
using ImageNet-trained AlexNet was able to improve the performance of 3D
tomosynthesis classification models.
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Figure 4.6 Loss converge status of 3D tomosynthesis classification models: (a) 3D-A1, (b)
3D-T1-Alex, (c) 3D-T2-Alex. (d) illustrates the ROC curves of different models.

Table 4.4 Validation results and optimized parameter combination of 3D tomosynthesis
classification models
Architecture
3D-A1
3D-T1-Alex
3D-T2-Alex

4.3.5

Batch Learning
L2 regularization
Dropout
auROC
size
rate
beta
128
0.01
0.5
0.001
0.6312
16
0.01
0.5
0.0001
0.6116
16
0.0001
0.5
0.0001
0.6632

Comparison of classification results of 2D mammogram and 3D tomosynthesis
Our current results suggest that the 2D mammogram classification model performs

slightly better than the 3D tomosynthesis classification model. However, radiologists
generally achieve better classification accuracy on 3D tomosynthesis data. One possible
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explanation for this phenomenon is that this study used only a subset of the 3D
tomosynthesis frames due to memory limitations and the consistent shape requirement of
the input. If the discarded frames contained information for diagnosing cancer that the
selected frames lacked, then the frame sampling may have contributed to significant
information loss. Another possible reason is that the 2D mammograms have better
resolution than the 3D tomosynthesis data used in this study, such that the 2D
mammograms may benefit from a higher signal-to-noise ratio [143].

4.4

Summary
This chapter reports our work on developing and optimizing machine learning

models for whole image classification of both 2D and 3D mammograms. We evaluated 10
different CNN architectures and conclude that combining both data augmentation and
transfer learning methods with a CNN is the most effective in improving classification
performance.
We report the first work that study both 2D and 3D mammography images for
breast cancer classification. Our current work sheds light on how each type of dataset
performs when trained independently. But in practice, 2D and 3D images are
complementary to each other, where 2D offers high resolution while 3D offers multiple
views. One of our future work is to develop an assembled classifier that integrates the 2D
and 3D data to achieve optimal performance.
3D tomosynthesis has proven to be much more powerful in manual detecting of
tumors in clinical practice than conventional 2D imaging. However, 3D data is much more
challenging to deal with, as it often corresponds to a much bigger feature space, requiring
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a larger training dataset to obtain better performance and requiring more memory space for
training. We believe there is still a great opportunity to improve the performance of 3D
image classification model. We are currently collecting more images while simultaneously
obtaining more precise annotation of each slice of 3D tomosynthesis data. Typically, only
a few frames in 3D images of a positive exam do contain the tumor. Using negative frames
within a positive exam may mislead the training of the model. In the meantime, we are also
investigating alternative strategies, such as RNN model, that can leverage the sequence
information among slices to perform classification.

81

CHAPTER 5. CONCLUSION
In the era of big data, transformation of biomedical big data into valuable biological
insights has become one of the most important challenges in bioinformatics. Large
quantities of biomedical data, including DNA/RNA sequencing data, and biomedical
imaging data, have been generated. Modern machine learning techniques, such as deep
learning, have been widely used in extracting meaningful patterns from big data sets. This
dissertation presents three novel machine learning applications in different but closely
related bioinformatics domains, two of them focus on next-generation sequencing data
analysis, and the other one is designed for biomedical imaging data analysis.
Alternative splicing is a regulated process that enables the production of multiple
mRNA transcripts from a single multi-exon gene. The availability of large-scale RNA-seq
datasets has made it possible to predict splice junctions, as well as splice sites through
spliced alignment to the reference genome. This greatly enhances the capability to decipher
gene structures and explore the diversity of splicing variants. However, existing ab initio
aligners are vulnerable to false positive spliced alignments as a result of sequence errors
and random sequence matches. These spurious alignments can lead to a significant set of
false positive splice junction predictions, confusing downstream analyses of splice variant
detection and abundance estimation. In chapter 2, we illustrated that splice junction
sequence characteristics can be ascertained from experimental data with deep learning
techniques. We employed deep convolutional neural networks for a novel splice junction
classification tool named DeepSplice. It performs better than the currently available splice
site prediction tools. We found that there is valuable information to be gained from splice
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junction sequences that conventional tools discard. The meaningful representations
learning from input sequences improve accuracy.
Metabolic reprogramming is a hallmark of cancer. In cancer cells, transcription
factors govern metabolic reprogramming through abnormally increasing or decreasing the
transcription rate of metabolic enzymes, which provides cancer cells growth advantages
and concurrently leads to the altered metabolic phenotypes observed in many cancers.
Consequently, targeting transcription factors that govern metabolic reprogramming can be
highly effective for novel cancer therapeutics. In chapter 3, we presented TFmeta, a
machine learning approach to uncover transcription factors that govern reprogramming of
cancer metabolism. Our approach achieves state-of-the-art performance in reconstructing
interactions between transcription factors and their target genes on benchmark data sets.
Leveraging TF binding profiles inferred from genome-wide ChIP-seq experiments and 150
RNA-seq samples from 75 paired cancerous and non-cancerous human lung tissues, our
approach predicted 19 key TFs that may be the major regulators of the gene expression
changes of metabolic enzymes of the central metabolic pathway glycolysis, which may
underlie the dysregulation of glycolysis in non-small-cell lung cancer patients.
Mammography is the most popular technology used for breast cancer early
detection. Manual classification of mammogram images is a difficult task because of the
variability of tumors, which yields a noteworthy number of patients being called back to
perform biopsies, ensuring no missing diagnosis. The convolutional neural network has
succeeded in lots of image classification challenges recent years. In chapter 4, we designed
an approach to perform 2D mammogram and 3D tomosynthesis classification based on
convolutional neural networks. Our study demonstrated that CNN-based models with data
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augmentation and transfer learning have good potential for automatic breast cancer
detection based on the mammograms and tomosynthesis data.
All software packages of the models described in this dissertation are open-source,
released, and freely available to the research community.
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